A message from our partner
Every now and then, New Scientist helps a carefully selected commercial partner speak to our audience. Their support helps us produce the high quality journalism we bring you every week. We hope you find today's message relevant and useful. |
|
|
 | | |  | | | | The third and fourth generations of CAR-T cells with ICOS/CD278 and 4-1BB/CD137 intracellular domains are more efficacious and persistent in their anti-tumor activity. The dual anti-CD19/CD20 CAR-T cells with these intracellular domains exhibit prolonged and enhanced cytokine generation. Co-expression of cytokines, like IL-2, IL-7, IL-12, IL-15, and IL-18, further improves the proliferation and survival of CAR-T cells. | | ICOS-BBz (ICOS+4-1BB) based CARs are promising therapeutics for testing in clinical trials. Sino Biological offers quality products for these co-stimulatory molecules and these related cytokines to support the research and development of CAR-T cells. | | | | Featured Recombinant ICOS and 4-1BB Proteins | | Sino Biological has a panel of verified and highly-cited recombinant ICOS, 4-1BB, and related proteins (e.g., ICOSL and CD137L/TNFSF9) to support CAR-T cell and cancer immunotherapy research. | | | 
High-purity | 
HPLC Verified | 
Activity Validated | | | 
High Lot-to-lot Consistency | 
Low-endotoxin | 
Cited by Researchers | | | | | | | More Related Targets | | | | | | |
|
|
This email has been sent to submitpostforlive@gmail.com.
Unsubscribe from further emails relating to selected third party partners from New Scientist. |
Do not reply directly to this email. If you have an enquiry, please contact us using the relevant contact details listed here. |
Copyright © New Scientist Ltd
Registered Office: Northcliffe House, 2 Derry Street, London, W8 5TT
Registered in England. No.10644366
Australian mailing address: PO Box 2315, Strawberry Hills, NSW 2012, Australia
Registered in Australia. ABN 22 621 413 170
Privacy Policy | Terms & Conditions |
|
|
|
|
|
|
